| __timestamp | Alnylam Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 504755000 |
| Thursday, January 1, 2015 | 60610000 | 838526000 |
| Friday, January 1, 2016 | 89354000 | 1177697000 |
| Sunday, January 1, 2017 | 199365000 | 1320433000 |
| Monday, January 1, 2018 | 382359000 | 1556200000 |
| Tuesday, January 1, 2019 | 479005000 | 1834800000 |
| Wednesday, January 1, 2020 | 588420000 | 1346000000 |
| Friday, January 1, 2021 | 620639000 | 1824900000 |
| Saturday, January 1, 2022 | 770658000 | 2115900000 |
| Sunday, January 1, 2023 | 795646000 | 2631300000 |
| Monday, January 1, 2024 | 975526000 | 2954400000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Regeneron's SG&A expenses surged by over 400%, peaking at approximately $2.63 billion in 2023. In contrast, Alnylam's expenses grew by a staggering 1,700%, reaching around $796 million in the same year.
Despite Regeneron's higher absolute costs, their growth rate was more controlled compared to Alnylam's. This suggests a more strategic allocation of resources, potentially contributing to Regeneron's robust market position. As the biotech industry continues to evolve, these insights into SG&A management offer valuable lessons for emerging companies aiming to balance growth with cost efficiency.
SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Regeneron Pharmaceuticals, Inc. vs Lantheus Holdings, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.